In vivo study for the hemostatic efficacy and foreign body reaction of a new powder-type polysaccharide hemostatic agent

Yoonhyeong Byun,Eun Jin Kim,Areum Lee,Young-Ah Suh,Hee Ju Sohn,Jung Min Lee,Jae Seung Kang,Yoo Jin Choi,Youngmin Han,Hongbeom Kim,Wooil Kwon,Jin-Young Jang 대한외과학회 2022 Annals of Surgical Treatment and Research(ASRT) Vol.102 No.2

Purpose: Various hemostatic agents have been introduced in therapy as postoperative bleeding is a poor prognostic factor for postoperative outcomes. These products can be divided into those that directly promote the hemostatic cascade and those that physically form a barrier by absorbing blood. The latter, powder-type hemostatic agents have the advantages of being inexpensive and more absorbable with less foreign body reactions (FBRs) and are applicable to a relatively wide area. This study was conducted to verify the safety and efficacy of a newly invented polysaccharide product (OOZFIX, Theracion Biomedical), which improves blood absorption and hemostatic effects. Methods: Two separate animal experiments were performed. The first evaluated FBRs histologically at 3 days, 2 weeks, and 4 weeks, after implantation of OOZFIX in rats, and the second compared hemostatic performance of OOZFIX and Arista AH (Bard) in the porcine liver punch biopsy model. Results: We found minimal FBRs in the 3-day group and no reactions in both the 2-week and 4-week groups after implantation of hemostatic agents. The time to hemostasis of OOZFIX was not significantly different from that of Arista AH (median [interquartile range]: 9 [6–10] minutes vs. 8 [6–10] minutes, respectively; P = 0.522). When comparing the serial bleeding grade tendency, there was no statistical difference between OOZFIX and Arista AH (P = 0.656). Conclusion: OOZFIX caused a minimal FBR that disappeared within 2 weeks in vivo, and its hemostatic performance was comparable with that of an existing agent, Arista AH. Further clinical studies are required in the future.

백혈병 세포에서 Multidrug Resistance Gene-1 (mdr1)의 과발현이 ^99m Tc-sestaMIBI 섭취에 미치는 영향

천경아,이재태,이상우,강도영,손상균,이종기,정준기,전수한,이규보 경북대학교 의학연구소 2000 경북대학교병원의학연구소논문집 Vol.4 No.1

Purpose: To determine whether 99mTc-MIBI is recognized by the multidrug resistant P-glycoprotein (Pgp), we have measured quantitatively 99mTc-MIBI uptake in cancer cells. The effects of various Pgp reversing agents on cellular 99mTc-MIBI uptake were also investigated in the presence of multidrug resistance gene-1(mdr1 gene) overexpression. Materisls and Methods: We measured percentage uptake of 99mTc-MIBI at different incubation temperatures both in mdr1 positive and negative cells. The effects of verapamil, cyclosporin, and dipyridamole on cellular uptake of 99mTc-MIBI were also evaluated with or withouts overexpression of mdr1 gene in Cultured murine leukemia L1210 cells. Results: The mdr1 gene expressing cell lines were effectively induced in in vitro with continuous application of low-dose adriamycin or vincristine. Cellular uptake of 99mTc-MIBI was higher in mdr1 negative L 1210 cells than those of mdr1 positive cells, and higher when incubated in 37℃ than 4℃. In the presence of verapamil, cyclosporin or dipyridamole, 99mTc-MIBI uptake was increased upto 604% in mdr1 positive cells. Conclusion: Cellular uptake of 99mTc-MIBI is lower in leukemia cells over-expressing mdr1 gene, and MDR-reversing agents increase cellular uptake. These results suggest that 99mTc-MIBI can be used for characterizing Pgp expression and developing MDR-reversing agents in vitro. (Korean J Nucl Med 1999;33: 152-62)

연폭로여성근로자들에서의 생물학적 연폭로 지표들의 상호관계

남택승,한구웅,김형아,김정만,이광묵 가톨릭대학 산업의학쎈타 산업의학연구소 1986 韓國의 産業醫學 Vol.25 No.3

For the purpose of obtaining of an effective biological monitoring data in terms of evaluation the health consequences of lead absorption, the female workers in the electronic industry who have been exposed to low-level lead occupationally were chosen as the subjects of our studies. We observed the 9 parameters in not only 305 lead-exposed female workers who have been exposed to lead occupationally also 254 normal female subjects who have not been exposed to lead occupationally. The parameters chosen for this study were as follows, blood lead (PbB), urine lead (PbU), δ-aminolevulinic acid in urine(ALAU), coproporphyrin in urine(CPU), zinc protoporphyrin in whole blood(ZPP), hemoglobin(Hb), hematocrit(Ht), δ-aminolevulinic acid dehydratase(ALAD) activity & ALAD activity ratio(A/R; absorbance at substrate pH 6.6/absorbance at substrate pH 5.8). The results obtained were as follows: 1. The average age of the lead-exposed female workers in the electronic industry and in the normal female subjects were 20.5±4.2 years and 21.7±3.5 years, respectively. 2. The average work duration of the lead-exposed female workers in the electronic industry was 26.4±19.4 months 3. The mean value of PbB of the lead-exposed female workers in the electronic industry and in the normal female subjects were 30.18±6.64㎍/100ml and 21.61±3.84㎍/100ml respectively. 4. In the lead-exposed female workers of the electronic industry and of the normal female subjects, the mean value of ZPP were 36.22±0.69㎍/100ml and 24.64±7.21㎍/100ml, respectively 5. In the lead-exposed female workers of the electronic industry and of the normal female subjects, the mean value of Hb were 13.98±0.57g/100ml and 14.09±0.66g/100ml, respectively. 6. The mean value of the lead-exposed female workers in the electronic industry were 55.07±17.61㎍/1 for PbU, 1.93±0.69mg/1 for ALAU, and 49.74±22.79㎍/1 for CPU, while in the normal female subjects, 44.27±15.76㎍/1 for PbU, 1.46±0.55mg/ 1 for ALAU, and 38.66±17.99㎍/1 for CPU. 7. Among various pairing of the parameters of lead exposure in the female lead-exposed workers and in the normal female subjects, the correlation between PbB and ZPP showed the highest coefficient value.

침 시술로 발생한 Non-O1, Non-O139 Vibrio cholerae에 의한 패혈증

임태섭,지아영,이중희,장수연,김인수,김영주,김범경,김승업,박준용,안상훈,한광협,김도영 Ewha Womans University School of Medicine 2013 EMJ (Ewha medical journal) Vol.36 No.S

Vibrio cholerae is mainly known to cause gastrointestinal infection after seawater exposure or raw seafood intake. It is rarely reported to cause cellulitis or sepsis, but threre has been no known case after acupuncture. Herein, We report a 56-year-old cirrhotic patient of non-O1, non-O139 Vibrio cholerae septicemia caused by cellulitis of both lower extremities after acupuncture.

In vitro Digestibility of Cooked Noodle Products

Jung-Ah Han,Tae-Rang Seo,Su-Jin Lee,Seung-Taik Lim 한국식품과학회 2007 Food Science and Biotechnology Vol.16 No.6

The in vitro digestive properties of 6 domestic noodle products (spaghetti, somyeon, ramyeon, dangmyeon, naengmyeon, and jjolmyeon) were compared after cooking under the manufacture’s recommended cooking conditions. The kinetic constant (k), representing the rate of hydrolysis at the initial digestion stage, was highest in the somyeon noodles (0.1151), followed by naengmyeon (0.0954), and was lowest in the spaghetti (0.0421). However, the concentration of starch (C∞) hydrolyzed over 2 hr was not different between the spaghetti (96.22) and the somyeon (96.40), indicating that different digestion behaviors occurred in each type of noodle, even though the amounts of digested starch were similar. The ramyeon, dangmyeon, and naengmyeon noodles showed relatively lower C∞ values than the spaghetti and the somyeon noodles. The spaghetti had the highest amount of slowly digestible starch (SDS, 43%) and the lowest glycemic index (GI, 87.8), whereas the somyeon had the lowest SDS value (9.6%) and the highest GI (93.0). The digestibility differences among the noodles were attributed to differences in their flour compositions and manufacturing processes.

Hepatitis B Core-Related Antigen Is a Satisfactory Marker in Differentiating Hepatitis B e Antigen-positive Chronic Infection and Hepatitis B e Antigen-Positive Chronic Hepatitis

( Han Ah Lee ),( Hyun Woong Lee ),( Jihwan Lim ),( Young-sun Lee ),( Young Kul Jung ),( Ji Hoon Kim ),( Jung Il Lee ),( Young Kul Jung ),( Hyung Joon Yim ),( Jong Eun Yeon ),( Kwan Soo Byun ),( Kwan S 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1

Aims: We investigated the clinical impact of Hepatitis B core-related antigen (HBcrAg) level in defining different phases of patients with chronic hepatitis B (CHB). Methods: Stored residual serum samples from longitudinal cohorts of CHB patients in Korea University College of Medicine were studied. Patients were divided into four phases of CHB based on the histology result: hepatitis B e antigen (HBeAg)-positive chronic infection (EPI), HBeAg-positive chronic hepatitis (EPH), HBeAg-negative chronic hepatitis (ENH), HBeAg-negative chronic infection (ENI). Results: In total, 425 patients followed up for 83.1 months were included. The number of patients in each phase are as follows: 26 in EPI, 243 in EPH, 137 in ENH, and 19 in EHI. To evaluate the clinical impact of HBCrAg in differentiating EPI and EPH, patients older than 60 years old, patients with clinically or ultrasonographically evident liver cirrhosis or fibrosis-4 index (> 3.25), and HBV-DNA ≤ 20,000 IU/mL were excluded. In 145 selected patients, 26 patients were in EPI and 119 patients were in EPH. HBCrAg level was significantly higher in EPI than in EPH (8.22 log U/mL vs. 7.57 log U/mL, P=0.003). On multivariate analysis, only higher HBCrAg level (HR 0.447, P=0.013) was significantly associated with an increased probability of EPI. To evaluate the clinical impact of HBCrAg in differentiating ENH and ENI, patients with clinically or ultrasonographically evident liver cirrhosis or fibrosis-4 index (> 3.25), and HBV-DNA > 20,000 IU/mL were excluded. In 33 selected patients, 21 patients were in ENH and 12 patients were ENI. HBCrAg level was significantly higher in ENH patients than in ENI patients (5.24 log U/mL vs. 3.98 log U/mL, P<0.001). Only elevated ALT according to the KASL criteria (HR 4.875, P=0.049) was significantly associated with increased probability of ENH. Conclusions: HBcrAg level is a useful marker in differentiating EPI and EPH in patients with CHB.

Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B

( Han Ah Lee ),( Yeon Seok Seo ),( Seung Woon Park ),( Sang Jung Park ),( Tae Hyung Kim ),( Sang Jun Suh ),( Young Kul Jung ),( Ji Hoon Kim ),( Hyunggin An ),( Hyung Joon Yim ),( Jong Eun Yeon ),( Kwa 대한간학회 2016 Clinical and Molecular Hepatology(대한간학회지) Vol.22 No.3

Background/Aims: Clear indicators for stopping antiviral therapy in chronic hepatitis B (CHB) patients are not yet available. Since the level of hepatitis B surface antigen (HBsAg) is correlated with covalently closed circular DNA, the HBsAg titer might be a good indicator of the off-treatment response. This study aimed to determine the relationship between the HBsAg titer and the entecavir (ETV) off-treatment response. Methods: This study analyzed 44 consecutive CHB patients (age, 44.6±11.4 years, mean±SD; men, 63.6%; positive hepatitis B envelope antigen (HBeAg) at baseline, 56.8%; HBV DNA level, 6.8±1.3 log10 IU/mL) treated with ETV for a sufficient duration and in whom treatment was discontinued after HBsAg levels were measured. A virological relapse was defined as an increase in serum HBV DNA level of >2000 IU/mL, and a clinical relapse was defined as a virological relapse with a biochemical flare, defined as an increase in the serum alanine aminotransferase level of >2 × upper limit of normal. Results: After stopping ETV, virological relapse and clinical relapse were observed in 32 and 24 patients, respectively, during 20.8±19.9 months of follow-up. The cumulative incidence rates of virological relapse were 36.2% and 66.2%, respectively, at 6 and 12 months, and those of clinical relapse were 14.3% and 42.3%. The off-treatment HBsAg level was an independent factor associated with clinical relapse (hazard ratio, 2.251; 95% confidence interval, 1.076-4.706; P=0.031). When patients were grouped according to off-treatment HBsAg levels, clinical relapse did not occur in patients with an off-treatment HBsAg level of ≤2 log10 IU/mL (n=5), while the incidence rates of clinical relapse at 12 months after off-treatment were 28.4% and 55.7% in patients with off-treatment HBsAg levels of >2 and ≤3 log10 IU/mL (n=11) and >3 log₁₀ IU/mL (n=28), respectively. Conclusions: The off-treatment HBsAg level is closely related to clinical relapse after treatment cessation. A serum HBsAg level of <2 log₁₀ IU/mL is an excellent predictor of a sustained off-treatment response in CHB patients who have received ETV for a sufficient duration. (Clin Mol Hepatol 2016;22:382-389)

Effects of Functional Soy Yogurt on the Loperamide-Induced Constipation in Rats

Jung-Ah Lee,Seo-Hee Han,Shin-Wook Choi,Hye-Jung Choi,Sun Yoon 한국식품영양과학회 2011 한국식품영양과학회 학술대회발표집 Vol.2011 No.10

In Vitro Digestibility of Rice and Barley in Forms of Raw Flour and Cooked Kernels

Jung-Ah Han,Su-Hae Jang,Seung-Taik Lim 한국식품과학회 2008 Food Science and Biotechnology Vol.17 No.1

Digestion properties of 3 types of cereals, white rice, brown rice, and barley, were measured after cooking or grinding. Regardless of the processing methods, white rice showed the highest rate and the greatest extent of digestion, whereas barley showed the lowest values. During the early digestion period, cooked white rice kernels had a larger k (kinetic constant) value than uncooked white rice flour, indicating that cooking induced faster digestion than grinding. In the case of brown rice and barley, the cell wall in cooked kernels remained intact and resulted in a lower k values than those of uncooked flour. However, after 3 hr of digestion, the total digestion extent was greater for the cooked brown rice and barley than that for uncooked flours. The high content of slowly digestible starch (SDS) in cooked brown rice and barley might be due to the starch fraction which was protected by the cell wall. The resistant starch (RS) content, however, was greater for the uncooked flours than that for cooked kernels. The cooked kernels of 3 cereal samples tested showed higher glycemic index (GI) values than the uncooked flours.

Hepatitis B Surface Antigen Titer Is a Good Indicator of Durable Viral Response after Off-treatment of Entecavir for Chronic Hepatitis B

( Han Ah Lee ),( Seung Woon Park ),( Sang Jung Park ),( Tae Hyung Kim ),( Sang Jun Suh ),( Young Kul Jung ),( Ji Hoon Kim ),( Hyung Joon Yim ),( Jong Eun Yeon ),( Kwan Soo Byun ),( Soon Ho Um ),( Yeon 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1

Aims: Definite guideline for stopping antiviral therapy for chronic hepatitisB (CHB) is not clarified yet. Previous studies suggested thatHBsAg titer is correlated with covalently closed circular DNA.Therefore, HBsAg titer might be a good indicator for off-treatment.This study was performed to determine the relationship betweenHBsAg titer and CHB relapse after off-treatment of entecavir (ETV).Methods: Patients in whom ETV was discontinued after serum HBVwith or without HBeAg clearance for more than 12 months andwho measured HBsAg titer at off-treatment were enrolled. HBV DNAreactivation was defined as increase of serum HBV DNA level >2000IU/mL, while CHB relapse was defined as HBV DNA reactivation andincrease of serum ALT level >2XULN.Results: Forty-four patients were enrolled. Age was 44.6±11.4 yearsand 28 patients (63.6%) were men. Baseline HBeAg was positive25 patients (56.8%) and serum HBV DNA level was 6.8±1.3 log10IU/mL. ETV was discontinued after 34.7±19.0 months of treatment.In HBeAg-positive CHB patients, ETV was discontinued after37.0±20.2 months of treatment, which was 31.0±19.5 and23.4±16.1 months after serum HBV DNA and HBeAg clearance,respectively. In HBeAg-negative CHB patients, ETV was discontinued after 31.6±17.4 months of treatment, which was 27.1±17.7 monthsafter serum HBV DNA clearance. HBsAg titer at off-treatment was3.0±1.0 log10 IU/mL, which was <2, 2~3, and >3 log10 IU/mL in5 (11.4%), 11 (25.0%), and 28 (63.6%) patients, respectively. Afteroff-treatment, HBV DNA reactivated in 38.7% and 66.2% and CHBwas relapsed in 4.7% and 42.3% at 6 and 12 months after off-treatment,respectively. HBsAg titer at off-treatment was significantly associatedwith HBV DNA reappearance (P=0.010) and CHB relapse(P=0.010).Conclusions: HBsAg titer at off-treatment is closely related with HBVreactivation and CHB relapse. HBsAg titer is considered as an excellentindicator of durable viral response after off-treatment.